Genomic surveillance of Lassa virus in Guinea through in-country sequencing

Strengthening in-country sequencing capacity in Guinea generated 28 Lassa virus genomes that revealed cross-border transmission dynamics with Liberia and Sierra Leone, highlighting the critical role of enhanced genomic surveillance in guiding future public health actions.

The Gist

Imagine Guinea as a vast, dense forest where a silent, invisible traveler called the Lassa virus lives. This virus doesn't just sit still; it hops between animals (specifically a type of rat) and occasionally jumps into humans, causing a dangerous illness called Lassa fever.

For a long time, scientists trying to track this virus were like detectives trying to solve a mystery with only half a clue. They knew the virus existed, but they didn't have a clear map of where it was hiding, how it was moving, or how it was changing over time.

Here is the story of how a team of scientists finally turned on the lights in that dark forest, explained simply:

1. Building a Local "Super-Scanner"

In the past, if a doctor in Guinea found a sick patient, they often had to send the blood sample to a lab in Europe or the US to get the virus's genetic code (its "fingerprint"). This took weeks, and by the time the answer came back, the virus might have already moved on.

The Change: The researchers built a high-tech "super-scanner" right inside Guinea. They set up a network of three labs—one in the capital, Conakry, and two in the forest regions. Think of this like installing security cameras and fingerprint scanners directly at the crime scene instead of mailing evidence to a distant headquarters.

2. The "Genetic Time Machine"

Using this new local equipment, the team sequenced the genetic code of the virus from 28 different patients.

Imagine the virus's genetic code as a long, ancient storybook. Every time the virus copies itself, it makes tiny typos. By reading these typos, scientists can act like time travelers:

• How old is the virus? They found that the main family of this virus (called Lineage IV) has been living in Guinea since the 17th or 18th century. That's older than the United States! It has been quietly circulating in the local rat population for hundreds of years.
• Where did it come from? The "storybook" showed that the virus likely started in the deep, forested southeast of Guinea and slowly spread out.

3. The "Border Crossers"

One of the most exciting discoveries was seeing how the virus travels across borders, even though countries have walls on a map.

• The Sierra Leone Visitor: They found a case in Guinea that was actually a "tourist" from Sierra Leone. The virus had jumped from the Kenema area of Sierra Leone into Guinea. It's like finding a specific brand of coffee in a shop in Paris that was definitely brewed in a café in London.
• The Liberian Connection: In the N'Zérékoré region, they found two different "families" of the virus. One had lived there for a long time, but the other was a recent arrival from Ganta, Liberia. It's like finding two different dialects of the same language being spoken in the same town, one local and one imported.

4. The "Mix-and-Match" Mystery (The Reassortant)

The most surprising twist happened in the capital city, Conakry. Four people got sick in a hospital outbreak. When the scientists looked at their virus, they found something weird: The virus had swapped parts.

Lassa virus has two segments of genetic code (let's call them Segment A and Segment B).

• Usually, a virus keeps its own A and B together.
• But in these four patients, the virus had Segment A from a strain found in the Guéckédou region and Segment B from a strain found in the Faranah region.

The Analogy: Imagine you buy a car. The engine comes from a Ford, but the wheels come from a Toyota. The scientists found a "Frankenstein" virus that mixed and matched its parts. This happened because two different versions of the virus infected the same person at the same time and swapped their genetic "Lego blocks."

Why Does This Matter?

This study is like upgrading from a blurry, black-and-white photo to a high-definition, 4K video of the virus's life.

• Better Maps: Now, health officials know exactly where the virus is hiding and how it moves between Guinea, Liberia, and Sierra Leone.
• Faster Responses: Because the labs are local, they can spot an outbreak and track it in real-time, rather than waiting weeks for results from abroad.
• Future Weapons: Understanding the virus's "family tree" helps scientists design better vaccines and tests that work against the specific versions of the virus circulating in West Africa today.

In short: By building a local lab and reading the virus's genetic story, scientists in Guinea have turned a shadowy mystery into a clear map, helping them protect their communities from this ancient, traveling enemy.

Technical Summary

1. Problem Statement

Lassa fever, caused by the Lassa virus (LASV), is an endemic viral hemorrhagic disease in West Africa. Despite its public health significance, genomic surveillance in Guinea has historically been limited.

• Data Scarcity: Prior to this study, genomic data from human clinical cases in Guinea was extremely sparse, with only a few partial genomes available (e.g., a 2019 case). Most existing data came from rodent reservoirs or neighboring countries.
• Surveillance Gaps: The lack of in-country sequencing capacity meant that viral diversity, transmission dynamics, cross-border spread, and the emergence of new variants were poorly understood. This hindered the development of targeted diagnostics, vaccines, and public health interventions.
• Clinical Complexity: Early symptoms of Lassa fever overlap with other febrile illnesses, making case detection difficult without robust molecular surveillance.

2. Methodology

The study leveraged a capacity-strengthening initiative launched in 2021 to establish and utilize in-country genomic sequencing infrastructure.

• Study Sites & Network: The research utilized a network of three laboratories in Guinea:
  1. CRV-LFHVG: National reference laboratory in Conakry.
  2. LFHV-GKD: Satellite laboratory in Guéckédou (Forest region).
  3. LFHV-HRNZE: Satellite laboratory in N'Zérékoré.
• Sample Collection: Between 2020 and 2024, the network confirmed 36 Lassa fever cases. From these, 28 cases were selected for sequencing based on sufficient viral load (RT-PCR positive).
• Sequencing Workflow:
  • Platform: Oxford Nanopore Technologies (MinION) using metagenomic approaches.
  • Library Prep: Viral RNA was extracted, treated with DNase, and subjected to Sequence Independent Single Primer Amplification (SISPA) to generate libraries without prior knowledge of the specific viral strain.
  • Bioinformatics: Consensus genomes were generated using the ViMOP pipeline (and previously minimap2/CANU). Sequences were base-called with Dorado v0.7.2.
• Phylogenetic & Phylogeographic Analysis:
  • Data: 28 new genomes (S and L segments) were combined with publicly available LASV sequences from Guinea, Sierra Leone, and Liberia.
  • Models: Bayesian phylogenetic inference was performed using BEAST X with a GTR+Γ4 substitution model, uncorrelated lognormal relaxed molecular clock, and Bayesian skygrid coalescent prior.
  • Spatial Modeling: A Relaxed Random Walk model was used to reconstruct viral dispersal history.
  • Reassortment Detection: The RDP4 software suite was used to detect segment reassortment (recombination of S and L segments).

3. Key Contributions

• Capacity Building: Demonstrated the successful establishment of a functional, in-country metagenomic sequencing pipeline in Guinea, moving away from reliance on external sequencing facilities.
• Dataset Expansion: Generated 28 high-quality LASV genomes from human clinical cases, significantly expanding the available genomic data for the region (previously limited to partial rodent genomes or single human cases).
• Methodological Integration: Integrated untargeted metagenomic sequencing into routine diagnostic workflows for viral hemorrhagic fevers, allowing for the detection of diverse viral strains.

4. Key Results

• Genomic Coverage: All 28 cases yielded sufficient coverage (36–100%). 20/28 S-segments and 18/28 L-segments had >90% coverage. All sequences belonged to Lineage IV, the predominant lineage in the Mano River Union.
• Evolutionary History:
  • The root of Lineage IV was estimated to originate in the 17th–18th centuries in southeastern (forested) Guinea.
  • Substitution rates were estimated at $8.5 \times 10^{-3}$ (S segment) and $8.2 \times 10^{-3}$ (L segment) substitutions/site/year.
• Geographic Clustering & Transmission Dynamics:
  • N'Zérékoré Region: Two co-circulating sub-lineages were identified:
    • IVb: A locally established, older lineage.
    • IVa: A lineage resulting from multiple independent introductions from Ganta, Liberia (dating back to the 1950s–1980s).
  • Guéckédou Region: Detected an imported case (G0959) originating from Kenema, Sierra Leone, confirming cross-border transmission.
  • Faranah Region: Identified as a distinct geographic cluster, though sampling bias (rodent vs. human) was noted.
• Nosocomial Outbreak & Reassortment:
  • Four cases from a 2022 nosocomial outbreak in Conakry were sequenced.
  • These strains showed minimal mutation (0–4 mutations in L, 0–1 in S), confirming a single transmission chain.
  • Critical Finding: These four genomes were identified as reassortants. Their S-segments clustered with Guéckédou (IVb) strains, while their L-segments clustered with Faranah strains. This is the first documentation of such reassortment in a human outbreak context in this region.

5. Significance

• Public Health Policy: The findings highlight that Lassa virus circulation in Guinea is dynamic, involving significant cross-border exchange with Liberia and Sierra Leone. This necessitates regional, rather than just national, surveillance strategies.
• Viral Evolution: The identification of reassortant strains in a nosocomial setting suggests that co-infection and segment swapping can occur in humans, potentially leading to novel variants with altered pathogenicity or transmissibility.
• Diagnostic & Therapeutic Development: The expanded genomic dataset provides a crucial baseline for designing accurate RT-PCR primers, developing monoclonal antibodies, and creating vaccines that cover the specific diversity of Lineage IV in Guinea.
• Model for Low-Resource Settings: The study serves as a blueprint for other low-income countries to develop local genomic surveillance capabilities, reducing dependency on external labs and accelerating outbreak response.

In conclusion, this research underscores the critical need for sustained, in-country genomic surveillance to monitor viral evolution, track cross-border transmission, and guide effective public health interventions for Lassa fever in West Africa.